Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 20 de 118
Filtrar
1.
Sci Rep ; 6: 38711, 2016 12 09.
Artículo en Inglés | MEDLINE | ID: mdl-27934952

RESUMEN

N-acetylglutamate synthase (NAGS; E.C.2.3.1.1) catalyzes the formation of N-acetylglutamate (NAG) from acetyl coenzyme A and glutamate. In microorganisms and plants, NAG is the first intermediate of the L-arginine biosynthesis; in animals, NAG is an allosteric activator of carbamylphosphate synthetase I and III. In some bacteria bifunctional N-acetylglutamate synthase-kinase (NAGS-K) catalyzes the first two steps of L-arginine biosynthesis. L-arginine inhibits NAGS in bacteria, fungi, and plants and activates NAGS in mammals. L-arginine increased thermal stability of the NAGS-K from Maricaulis maris (MmNAGS-K) while it destabilized the NAGS-K from Xanthomonas campestris (XcNAGS-K). Analytical gel chromatography and ultracentrifugation indicated tetrameric structure of the MmMNAGS-K in the presence and absence of L-arginine and a tetramer-octamer equilibrium that shifted towards tetramers upon binding of L-arginine for the XcNAGS-K. Analytical gel chromatography of mouse NAGS (mNAGS) indicated either different oligomerization states that are in moderate to slow exchange with each other or deviation from the spherical shape of the mNAGS protein. The partition coefficient of the mNAGS increased in the presence of L-arginine suggesting smaller hydrodynamic radius due to change in either conformation or oligomerization. Different effects of L-arginine on oligomerization of NAGS may have implications for efforts to determine the three-dimensional structure of mammalian NAGS.


Asunto(s)
Alphaproteobacteria/enzimología , N-Acetiltransferasa de Aminoácidos/química , Arginina/química , Proteínas Bacterianas/química , Multimerización de Proteína , Xanthomonas campestris/enzimología , N-Acetiltransferasa de Aminoácidos/metabolismo , Animales , Arginina/metabolismo , Proteínas Bacterianas/metabolismo , Estructura Cuaternaria de Proteína
2.
Ann Oncol ; 26(5): 1025-1030, 2015 May.
Artículo en Inglés | MEDLINE | ID: mdl-25672894

RESUMEN

BACKGROUND: A previously carried out randomized phase IIb, placebo-controlled trial of 1 year of inhaled budesonide, which was nested in a lung cancer screening study, showed that non-solid and partially solid lung nodules detected by low-dose computed tomography (LDCT), and not immediately suspicious for lung cancer, tended to regress. Because some of these nodules may be slow-growing adenocarcinoma precursors, we evaluated long-term outcomes (after stopping the 1-year intervention) by annual LDCT. PATIENTS AND METHODS: We analyzed the evolution of target and non-target trial nodules detected by LDCT in the budesonide and placebo arms up to 5 years after randomization. The numbers and characteristics of lung cancers diagnosed during follow-up were also analyzed. RESULTS: The mean maximum diameter of non-solid nodules reduced significantly (from 5.03 mm at baseline to 2.61 mm after 5 years) in the budesonide arm; there was no significant size change in the placebo arm. The mean diameter of partially solid lesions also decreased significantly, but only by 0.69 mm. The size of solid nodules did not change. Neither the number of new lesions nor the number of lung cancers differed in the two arms. CONCLUSIONS: Inhaled budesonide given for 1 year significantly decreased the size of non-solid nodules detected by screening LDCT after 5 years. This is of potential importance since some of these nodules may progress slowly to adenocarcinoma. However, further studies are required to assess clinical implications. CLINICAL TRIAL NUMBER: NCT01540552.


Asunto(s)
Adenocarcinoma/prevención & control , Antineoplásicos/administración & dosificación , Budesonida/administración & dosificación , Neoplasias Pulmonares/prevención & control , Nódulos Pulmonares Múltiples/tratamiento farmacológico , Lesiones Precancerosas/tratamiento farmacológico , Nódulo Pulmonar Solitario/tratamiento farmacológico , Adenocarcinoma/diagnóstico por imagen , Adenocarcinoma del Pulmón , Administración por Inhalación , Antineoplásicos/efectos adversos , Budesonida/efectos adversos , Ensayos Clínicos Fase II como Asunto , Detección Precoz del Cáncer/métodos , Humanos , Neoplasias Pulmonares/diagnóstico por imagen , Tomografía Computarizada Multidetector , Nódulos Pulmonares Múltiples/diagnóstico por imagen , Lesiones Precancerosas/diagnóstico por imagen , Valor Predictivo de las Pruebas , Ensayos Clínicos Controlados Aleatorios como Asunto , Estudios Retrospectivos , Factores de Riesgo , Nódulo Pulmonar Solitario/diagnóstico por imagen , Factores de Tiempo , Resultado del Tratamiento
3.
Ann Oncol ; 26(1): 47-57, 2015 Jan.
Artículo en Inglés | MEDLINE | ID: mdl-25096604

RESUMEN

BACKGROUND: Accumulating evidence supports an effect of aspirin in reducing overall cancer incidence and mortality in the general population. We reviewed current data and assessed the benefits and harms of prophylactic use of aspirin in the general population. METHODS: The effect of aspirin for site-specific cancer incidence and mortality, cardiovascular events was collated from the most recent systematic reviews. Studies identified through systematic Medline search provided data regarding harmful effects of aspirin and baseline rates of harms like gastrointestinal bleeding and peptic ulcer. RESULTS: The effects of aspirin on cancer are not apparent until at least 3 years after the start of use, and some benefits are sustained for several years after cessation in long-term users. No differences between low and standard doses of aspirin are observed, but there were no direct comparisons. Higher doses do not appear to confer additional benefit but increase toxicities. Excess bleeding is the most important harm associated with aspirin use, and its risk and fatality rate increases with age. For average-risk individuals aged 50-65 years taking aspirin for 10 years, there would be a relative reduction of between 7% (women) and 9% (men) in the number of cancer, myocardial infarction or stroke events over a 15-year period and an overall 4% relative reduction in all deaths over a 20-year period. CONCLUSIONS: Prophylactic aspirin use for a minimum of 5 years at doses between 75 and 325 mg/day appears to have favourable benefit-harm profile; longer use is likely to have greater benefits. Further research is needed to determine the optimum dose and duration of use, to identify individuals at increased risk of bleeding, and to test effectiveness of Helicobacter pylori screening-eradication before starting aspirin prophylaxis.


Asunto(s)
Aspirina/efectos adversos , Aspirina/uso terapéutico , Infarto del Miocardio/prevención & control , Neoplasias/prevención & control , Accidente Cerebrovascular/prevención & control , Antiinflamatorios no Esteroideos/efectos adversos , Antiinflamatorios no Esteroideos/uso terapéutico , Femenino , Hemorragia Gastrointestinal/inducido químicamente , Humanos , Masculino
4.
Mol Endocrinol ; 26(2): 220-7, 2012 Feb.
Artículo en Inglés | MEDLINE | ID: mdl-22174377

RESUMEN

The coregulator steroid receptor coactivator (SRC)-1 increases transcriptional activity of the estrogen receptor (ER) in a number of tissues including bone. Mice deficient in SRC-1 are osteopenic and display skeletal resistance to estrogen treatment. SRC-1 is also known to modulate effects of selective ER modulators like tamoxifen. We hypothesized that single nucleotide polymorphisms (SNP) in SRC-1 may impact estrogen and/or tamoxifen action. Because the only nonsynonymous SNP in SRC-1 (rs1804645; P1272S) is located in an activation domain, it was examined for effects on estrogen and tamoxifen action. SRC-1 P1272S showed a decreased ability to coactivate ER compared with wild-type SRC-1 in multiple cell lines. Paradoxically, SRC-1 P1272S had an increased protein half-life. The Pro to Ser change disrupts a putative glycogen synthase 3 (GSK3)ß phosphorylation site that was confirmed by in vitro kinase assays. Finally, knockdown of GSK3ß increased SRC-1 protein levels, mimicking the loss of phosphorylation at P1272S. These findings are similar to the GSK3ß-mediated phospho-ubiquitin clock previously described for the related coregulator SRC-3. To assess the potential clinical significance of this SNP, we examined whether there was an association between SRC-1 P1272S and selective ER modulators response in bone. SRC-1 P1272S was associated with a decrease in hip and lumbar bone mineral density in women receiving tamoxifen treatment, supporting our in vitro findings for decreased ER coactivation. In summary, we have identified a functional genetic variant of SRC-1 with decreased activity, resulting, at least in part, from the loss of a GSK3ß phosphorylation site, which was also associated with decreased bone mineral density in tamoxifen-treated women.


Asunto(s)
Antineoplásicos Hormonales/efectos adversos , Glucógeno Sintasa Quinasa 3/metabolismo , Coactivador 1 de Receptor Nuclear/genética , Tamoxifeno/efectos adversos , Secuencia de Aminoácidos , Sustitución de Aminoácidos , Antineoplásicos Hormonales/uso terapéutico , Desmineralización Ósea Patológica/inducido químicamente , Desmineralización Ósea Patológica/genética , Densidad Ósea/efectos de los fármacos , Neoplasias de la Mama/prevención & control , Línea Celular Tumoral , Ensayos Clínicos como Asunto , Femenino , Estudios de Asociación Genética , Glucógeno Sintasa Quinasa 3 beta , Humanos , Datos de Secuencia Molecular , Fosforilación , Polimorfismo de Nucleótido Simple , Procesamiento Proteico-Postraduccional , Estabilidad Proteica , Receptores de Estrógenos/agonistas , Receptores de Estrógenos/metabolismo , Análisis de Secuencia de ADN , Tamoxifeno/uso terapéutico
5.
Ann Bot ; 105(7): 1073-80, 2010 Jun.
Artículo en Inglés | MEDLINE | ID: mdl-20430785

RESUMEN

BACKGROUND: Plants require at least 14 mineral elements for their nutrition. These include the macronutrients nitrogen (N), phosphorus (P), potassium (K), calcium (Ca), magnesium (Mg) and sulphur (S) and the micronutrients chlorine (Cl), boron (B), iron (Fe), manganese (Mn), copper (Cu), zinc (Zn), nickel (Ni) and molybdenum (Mo). These are generally obtained from the soil. Crop production is often limited by low phytoavailability of essential mineral elements and/or the presence of excessive concentrations of potentially toxic mineral elements, such as sodium (Na), Cl, B, Fe, Mn and aluminium (Al), in the soil solution. SCOPE: This article provides the context for a Special Issue of the Annals of Botany on 'Plant Nutrition for Sustainable Development and Global Health'. It provides an introduction to plant mineral nutrition and explains how mineral elements are taken up by roots and distributed within plants. It introduces the concept of the ionome (the elemental composition of a subcellular structure, cell, tissue or organism), and observes that the activities of key transport proteins determine species-specific, tissue and cellular ionomes. It then describes how current research is addressing the problems of mineral toxicities in agricultural soils to provide food security and the optimization of fertilizer applications for economic and environmental sustainability. It concludes with a perspective on how agriculture can produce edible crops that contribute sufficient mineral elements for adequate animal and human nutrition.


Asunto(s)
Desarrollo de la Planta , Plantas/metabolismo , Agricultura , Fertilizantes , Minerales/metabolismo , Proteínas de Plantas/genética , Proteínas de Plantas/metabolismo
6.
Sex Plant Reprod ; 22(1): 37-44, 2009 Mar.
Artículo en Inglés | MEDLINE | ID: mdl-20033454

RESUMEN

Low capsule and seed set is a major factor limiting seed production in Eucalyptus globulus seed orchards. Controlled pollination studies showed that the reproductive success (number of seeds produced per flower pollinated) was primarily determined by the female. We aimed to identify the factors contributing to the differences in reproductive success between female genotypes in terms of the physical and anatomical properties of the flower. We studied pairs of genotypes of high and low reproductive success from each of three races (Furneaux Group, Strzelecki Ranges and Western Otways) growing in a seed orchard. Controlled pollinations were performed on six females and along with flower physical measurements, pollen tube growth and seed set were assessed. Overall tree reproductive success was positively correlated with flower size, ovule numbers, style size, cross-sectional area of conductive tissue within the style (all of which were inter-correlated) and the proportion of pollen tubes reaching the bottom of the style. Significant positive correlations of reproductive success and flower physical properties between different ramets of the same genotypes across seasons suggests a genetic basis to the variation observed. The majority of pollen tube attrition occurred within the first millimetre of the cut style and appeared to be associated with differences in style physiology. When examined as pairs within races the difference in reproductive success for the Western Otways pair was simply explained by differences in flower size and the number of ovules per flower. Physical features did not differ significantly for the Strzelecki Ranges pair, but the proportion of pollen tubes reaching the bottom of the style was lower in the less reproductively successful genotype, suggesting an endogenous physiological constraint to pollen tube growth. The difference in reproductive success between the females from the Furneaux Group was associated with a combination of these factors.


Asunto(s)
Eucalyptus/fisiología , Flores/fisiología , Polinización/fisiología , Eucalyptus/crecimiento & desarrollo , Tubo Polínico/crecimiento & desarrollo , Tubo Polínico/fisiología
7.
Br J Cancer ; 98(8): 1380-8, 2008 Apr 22.
Artículo en Inglés | MEDLINE | ID: mdl-18362934

RESUMEN

Retinoids, vitamin A analogues that bind to retinoic acid receptor (RAR) or retinoid X receptor (RXR), play important roles in regulating cell proliferation, apoptosis, and differentiation. Recently, RXR-selective ligands, also referred to as rexinoids, have been investigated as potential chemopreventive agents for breast cancer. Our previous studies demonstrated that the rexinoid bexarotene significantly prevented ER-negative mammary tumourigenesis with less toxicity than naturally occurring retinoids in animal models. To determine whether bexarotene prevents cancer at the early stages during the multistage process of mammary carcinogenesis, we treated MMTV-erbB2 mice with bexarotene for 2 or 4 months. The development of preinvasive mammary lesions such as hyperplasias and carcinoma-in-situ was significantly inhibited. This inhibition was associated with reduced proliferation, but no induction of apoptosis. We also examined the regulation of a number of rexinoid-modulated genes including critical growth and cell cycle regulating genes using breast cell lines and mammary gland samples from mice treated with rexinoids. We showed that two of these genes (DHRS3 and DEC2) were modulated by bexarotene both in vitro and in vivo. Identification of these rexinoid-modulated genes will help us understand the mechanism by which rexinoid prevents cancer. Such rexinoid-regulated genes also represent potential biomarkers to assess the response of rexinoid treatment in clinical trials.


Asunto(s)
Anticarcinógenos/uso terapéutico , Genes erbB-2 , Neoplasias Mamarias Experimentales/prevención & control , Virus del Tumor Mamario del Ratón/genética , Lesiones Precancerosas/prevención & control , Tetrahidronaftalenos/uso terapéutico , Animales , Factores de Transcripción con Motivo Hélice-Asa-Hélice Básico/genética , Bexaroteno , Proliferación Celular/efectos de los fármacos , Ciclina D , Ciclinas/genética , Femenino , Perfilación de la Expresión Génica , Proteínas de Homeodominio/genética , Glándulas Mamarias Animales/efectos de los fármacos , Glándulas Mamarias Animales/crecimiento & desarrollo , Ratones , Ratones Transgénicos
8.
Oncogene ; 27(3): 366-77, 2008 Jan 10.
Artículo en Inglés | MEDLINE | ID: mdl-17637753

RESUMEN

The activating protein-1 (AP-1) transcription factor transduces growth signals through signal transduction pathways to the nucleus, leading to the expression of genes involved in growth and malignant transformation in many cell types. We have previously shown that overexpression of a dominant negative form of the cJun proto-oncogene, a cJun dominant negative mutant (Tam67), blocks AP-1 transcriptional activity, induces a G(1) cell cycle block and inhibits breast cancer cell growth in vitro and in vivo. We found that AP-1 blockade by Tam67 in MCF-7 breast cancer cells downregulates cyclin D1 transcriptional activity by at least two mechanisms: by suppressing transcription at the known AP-1 binding site (-934/-928) and by suppressing growth factor-induced expression through suppressing E2F activation at the E2F-responsive site (-726/-719). AP-1 blockade also led to reduced expression of E2F1 and E2F2, but not E2F4, at the mRNA and protein levels. Chromatin immunoprecipitation and supershift assays demonstrated that AP-1 blockade caused decreased binding of E2F1 protein to the E2F site in the cyclin D1 promoter. We also found that Tam67 suppressed the expression of the E2F1 dimerizing partner, DP1 and E2F-upregulated cell cycle genes (cyclins E, A, B and D3) and enhanced the expression of E2F-downregulated cell cycle genes (cyclins G(2) and I). Reduced expression of other E2F-regulated genes was also seen with AP-1 blockade and E2F suppression. Thus, the AP-1 factor regulates the expression of cyclin D and E2F (the latter in turn regulates E2F-downstream genes), leading to cell cycle progression and breast cancer cell proliferation.


Asunto(s)
Neoplasias de la Mama/patología , Ciclina D1/antagonistas & inhibidores , Factores de Transcripción E2F/metabolismo , Factor de Transcripción AP-1/metabolismo , Neoplasias de la Mama/genética , Línea Celular Tumoral , Proliferación Celular , Inmunoprecipitación de Cromatina , Ciclina D1/genética , Ciclina D1/metabolismo , Ciclinas/genética , Ciclinas/metabolismo , Regulación hacia Abajo , Factores de Transcripción E2F/genética , Factor de Transcripción E2F1/genética , Factor de Transcripción E2F1/metabolismo , Factor de Transcripción E2F2/genética , Factor de Transcripción E2F2/metabolismo , Factor de Transcripción E2F4/genética , Factor de Transcripción E2F4/metabolismo , Femenino , Regulación Neoplásica de la Expresión Génica , Humanos , Fragmentos de Péptidos/metabolismo , Regiones Promotoras Genéticas , Proto-Oncogenes Mas , Proteínas Proto-Oncogénicas c-jun/metabolismo , ARN Mensajero/antagonistas & inhibidores , ARN Mensajero/metabolismo , Factor de Transcripción AP-1/antagonistas & inhibidores , Factor de Transcripción DP1/metabolismo
9.
Occup Environ Med ; 62(6): 414-6, 2005 Jun.
Artículo en Inglés | MEDLINE | ID: mdl-15901890

RESUMEN

Fluorocarbons are widely used in industry, and manifestations of inhalation toxicity include polymer fume fever, reactive airways dysfunction, and bronchospasm. Only seven cases of alveolitis occurring acutely after inhalation have been reported. This paper presents four cases of toxic pneumonitis due to direct inhalation of industrial fluorocarbon used as a waterproofing spray for horse rugs. These cases differ from previous reports and show that chronic as well as acute alveolitis can result from fluorocarbon inhalation. Corticosteroid treatment may be beneficial. The need for stricter control in the workplace is emphasised.


Asunto(s)
Fluorocarburos/toxicidad , Enfermedades Profesionales/inducido químicamente , Neumonía/inducido químicamente , Enfermedad Aguda , Adolescente , Adulto , Enfermedad Crónica , Femenino , Glucocorticoides/uso terapéutico , Humanos , Exposición por Inhalación/efectos adversos , Masculino , Enfermedades Profesionales/tratamiento farmacológico , Neumonía/tratamiento farmacológico
10.
Eur Respir J ; 21(4): 606-10, 2003 Apr.
Artículo en Inglés | MEDLINE | ID: mdl-12762343

RESUMEN

Patients with lung cancer present to and are managed by a variety of clinicians. In this study the effect of involvement by a respiratory physician on the diagnosis, staging, treatment and survival of a large unselected group of lung cancer patients was investigated. The study population was derived from the Scottish Cancer Registry. A total of 3,855 patients diagnosed during 1995 with lung cancer were studied. The data were validated and supplemented by references to medical records. The study found that a respiratory physician had been involved in the initial management of 2,901 (75.3%) patients. These patients were found more likely to have had the cancer diagnosis confirmed by histological methods and to have received active treatment with surgery, radiotherapy or chemotherapy. Survival, 1 yr after diagnosis was higher in patients who saw a respiratory physician (24.4 versus 11.1%) and benefit was found to have remained 3 yrs after diagnosis (8.1 versus 3.7%). Although the patients who had not seen a respiratory physician were generally older, and had more extensive disease, after correcting for age, stage and other prognostic factors, the relative hazard ratio of death for those not managed by a respiratory physician was 1.44. The data from this study supports the recommendations of recent lung cancer guidelines for the early involvement by a respiratory physician.


Asunto(s)
Neoplasias Pulmonares/diagnóstico , Neoplasias Pulmonares/terapia , Neumología , Adulto , Anciano , Anciano de 80 o más Años , Distribución de Chi-Cuadrado , Competencia Clínica , Femenino , Accesibilidad a los Servicios de Salud , Humanos , Masculino , Persona de Mediana Edad , Guías de Práctica Clínica como Asunto , Sistema de Registros
11.
Transgenic Res ; 11(6): 617-33, 2002 Dec.
Artículo en Inglés | MEDLINE | ID: mdl-12509137

RESUMEN

Breast cancer is a leading cause of cancer morbidity and mortality. Given that the majority of human breast cancers appear to be due to non-genetic factors, identifying agents and mechanisms of prevention is key to lowering the incidence of cancer. Genetically engineered mouse models of mammary cancer have been important in elucidating molecular pathways and signaling events associated with the initiation, promotion, and the progression of cancer. Since several transgenic mammary models of human breast cancer progress through well-defined cancer stages, they are useful pre-clinical systems to test the efficacy of chemopreventive and chemotherapeutic agents. This review outlines several oncogenic pathways through which mammary cancer can be induced in transgenic models and describes several types of preventive and therapeutic agents that have been tested in transgenic models of mammary cancer. The effectiveness of farnesyl inhibitors, aromatase inhibitors, differentiating agents, polyamine inhibitors, anti-angiogenic inhibitors, and immunotherapeutic compounds including vaccines have been evaluated in reducing mammary cancer and tumor progression in transgenic models.


Asunto(s)
Antineoplásicos/farmacología , Neoplasias Mamarias Experimentales/tratamiento farmacológico , Inhibidores de la Angiogénesis , Animales , Antineoplásicos/uso terapéutico , Ciclo Celular/efectos de los fármacos , Diferenciación Celular/efectos de los fármacos , Evaluación Preclínica de Medicamentos/métodos , Femenino , Inmunoterapia , Neoplasias Mamarias Experimentales/etiología , Ratones , Ratones Transgénicos , Transducción de Señal/efectos de los fármacos
12.
Biol Trace Elem Res ; 81(2): 127-39, 2001 Aug.
Artículo en Inglés | MEDLINE | ID: mdl-11554394

RESUMEN

Boron is an essential element for vascular plants and for diatoms, cyanobacteria, and a number of species of marine algal flagellates. Boron was recently established as an essential micronutrient for frogs (Xenopus laevis) and preliminary evidence suggests that it may be essential for all animals. The main form of B, which is available in the natural environment, is in the form of undissociated boric acid. The permeability coefficient and the mechanism of transport of boric acid, however, have not been experimentally determined across any animal membrane or cell. In the experiments described here, the permeability coefficient of boric acid in Xenopus oocytes was 1.5 x 10(-6) cm/s, which is very close with the permeability across liposomes made with phosphatidylcholine and cholesterol (the major lipids in the oocyte membrane). Moreover, we investigated the mechanism of boric acid movement across the membrane of Xenopus oocytes and we compared it with the transport across artificial liposomes. The transport of boric acid across Xenopus oocytes was not affected by inhibitors such as HgCl2, phloretin, or 4,4-diisothiocyanatostilbene-2,2'-D-sulfonic acid (DIDS). The kinetics of B uptake was linear with concentration changes, and the permeability remained the same at different external boric acid concentrations. These results suggest that B transport occurs via simple passive diffusion through the lipid bilayer in Xenopus oocytes.


Asunto(s)
Ácidos Bóricos/metabolismo , Membrana Celular/metabolismo , Oocitos/metabolismo , Xenopus laevis/embriología , Ácido 4,4'-Diisotiocianostilbeno-2,2'-Disulfónico/farmacología , Animales , Transporte Biológico , Colesterol/metabolismo , Difusión , Relación Dosis-Respuesta a Droga , Cinética , Membrana Dobles de Lípidos/metabolismo , Cloruro de Magnesio/farmacología , Permeabilidad , Floretina/farmacología , Fosfatidilcolinas/metabolismo , Factores de Tiempo
13.
Planta ; 213(1): 142-6, 2001 May.
Artículo en Inglés | MEDLINE | ID: mdl-11523650

RESUMEN

The permeability of biological membranes to boric acid was investigated using the giant internodal cells of the charophyte alga Chara corallina (Klein ex Will. Esk. R.D. Wood). The advantage of this system is that it is possible to distinguish between membrane transport of boron (B) and complexing of B by plant cell walls. Influx of B was found to be rapid, with equilibrium between the intracellular and extracellular phases being established after approximately 24 h when the external concentration was 50 microM. The intracellular concentration at equilibrium was 55 microM, which is consistent with passive distribution of B across the membrane along with a small amount of internal complexation. Efflux of B occurred with a similar half-time to influx, approximately 3 h, which indicates that the intracellular B was not tightly complexed. The concentration dependence of short-term influx measured with 10B-enriched boric acid was biphasic. This was tentatively attributed to the operation of two separate transport systems, a facilitated system that saturates at 5 microM, and a linear component due to simple diffusion of B through the membrane. Vmax and Km for the facilitated transport system were 135 pmol m(-2) s(-1) and 2 microM, respectively. The permeability coefficient for boric acid in the Chara plasmalemma estimated from the slope of the linear influx component was 4.4 x 10(-7) cm s(-1) which is an order of magnitude lower than computed from the ether:water partition coefficient for B.


Asunto(s)
Boro/metabolismo , Chlorophyta/metabolismo , Transporte Biológico , Permeabilidad de la Membrana Celular , Pared Celular/metabolismo , Espacio Extracelular/metabolismo , Líquido Intracelular/metabolismo , Cinética
14.
Oncogene ; 20(22): 2771-80, 2001 May 17.
Artículo en Inglés | MEDLINE | ID: mdl-11420689

RESUMEN

We have previously demonstrated that basal AP-1 transcriptional activity is high in normal human mammary epithelial cells, intermediate in immortal breast cells, and relatively low in breast cancer cells. In this study we investigated whether differences in AP-1 transcriptional activity reflect differences in breast cells' dependence on AP-1 for proliferation. The cJun dominant negative, TAM-67, was used to determine the effect of AP-1 blockade on the growth of normal, immortal and malignant breast cells. We first showed that TAM-67 inhibits AP-1 activity in normal and malignant breast cells. We then determined whether this AP-1 inhibitor affected colony forming efficiency of the immortalized and malignant breast cells. The AP-1 inhibitor reduced colony formation of immortal breast cells by over 50% (by 58% in 184B5 cells and 62% in MCF10A cells), and reduced colony formation in the breast cancer cell line MCF7 by 43%, but did not reduce colony formation in the other breast cancer cell lines (T47D, MDA MB231 and MDA MB 435). We also determined the effect of AP-1 blockade on the growth of normal breast cells using a single cell proliferation assay. Using this assay, the growth of normal breast cells was extremely sensitive to AP-1 blockade, while immortal breast cells were moderately sensitive. We next directly tested the effect of TAM-67 expression on the growth of MCF7 breast cancer cells, using cells stably transfected with TAM-67 under the control of a doxycycline-inducible promoter. Upon induction, TAM-67 was expressed and AP-1 activity was inhibited in these cells. We then measured the growth of these cells in the presence or absence of TAM-67. The results of these studies show that the growth of MCF7 cells was suppressed by the AP-1 inhibitor, TAM-67. These results demonstrate that normal and immortalized breast cells, and some breast cancer cells (such as MCF7), require AP-1 to transduce proliferative signals, while other breast cancer cells (such as T47D, MDA MB 231 and MDA MB 435) do not. These studies suggest that the AP-1 transcription factor is a potential target for future agents for the prevention or treatment of breast cancer.


Asunto(s)
Neoplasias de la Mama/patología , Mama/citología , División Celular/efectos de los fármacos , Factor de Transcripción AP-1/antagonistas & inhibidores , Mama/metabolismo , Neoplasias de la Mama/metabolismo , División Celular/fisiología , Femenino , Vectores Genéticos/metabolismo , Humanos , Proteínas Proto-Oncogénicas c-jun/genética , Proteínas Proto-Oncogénicas c-jun/metabolismo , Factor de Transcripción AP-1/metabolismo , Células Tumorales Cultivadas/efectos de los fármacos , Ensayo de Tumor de Célula Madre
15.
J Biol Chem ; 276(30): 27907-12, 2001 Jul 27.
Artículo en Inglés | MEDLINE | ID: mdl-11353774

RESUMEN

In a search for novel transcriptional intermediary factors for the estrogen receptor (ER), we used the ligand-binding domain and hinge region of ER as bait in a yeast two-hybrid screen of a cDNA library derived from tamoxifen-resistant MCF-7 human breast tumors from an in vivo athymic nude mouse model. Here we report the isolation and characterization of the forkhead homologue in rhabdomyosarcoma (FKHR), a recently described member of the hepatocyte nuclear factor 3/forkhead homeotic gene family, as a nuclear hormone receptor (NR) intermediary protein. FKHR interacts with both steroid and nonsteroid NRs, although the effect of ligand on this interaction varies by receptor type. The interaction of FKHR with ER is enhanced by estrogen, whereas its interaction with thyroid hormone receptor and retinoic acid receptor is ligand-independent. In addition, FKHR differentially regulates the transactivation mediated by different NRs. Transient transfection of FKHR into mammalian cells dramatically represses transcription mediated by the ER, glucocorticoid receptor, and progesterone receptor. In contrast, FKHR stimulates rather than represses retinoic acid receptor- and thyroid hormone receptor-mediated transactivation. Most intriguingly, overexpression of FKHR dramatically inhibits the proliferation of ER-dependent MCF-7 breast cancer cells. Therefore, FKHR represents a bifunctional NR intermediary protein that can act as either a coactivator or corepressor, depending on the receptor type.


Asunto(s)
Núcleo Celular/metabolismo , Proteínas de Unión al ADN/química , Rabdomiosarcoma/metabolismo , Factores de Transcripción/química , Secuencia de Aminoácidos , Animales , Western Blotting , Neoplasias de la Mama/metabolismo , Células COS , ADN Complementario/metabolismo , Proteína Forkhead Box O1 , Factores de Transcripción Forkhead , Biblioteca de Genes , Glutatión Transferasa/metabolismo , Humanos , Ligandos , Luciferasas/metabolismo , Ratones , Ratones Desnudos , Datos de Secuencia Molecular , Plásmidos/metabolismo , Unión Proteica , Estructura Terciaria de Proteína , Receptores de Estrógenos/metabolismo , Proteínas Recombinantes de Fusión/metabolismo , Homología de Secuencia de Aminoácido , Transducción de Señal , Distribución Tisular , Activación Transcripcional , Transfección , Células Tumorales Cultivadas , Técnicas del Sistema de Dos Híbridos
16.
Scott Med J ; 46(5): 150-2, 2001 Oct.
Artículo en Inglés | MEDLINE | ID: mdl-11771497

RESUMEN

Lymphangioleiornyomatosis is a rare lung disorder characterised by cystic air spaces and smooth muscle proliferation. The condition, which most commonly presents with dyspnoea, pneumothoraces or cough, is only described in females and is most commonly diagnosed during childbearing years. Three cases are presented which illustrate typical features of the disease and the association with high oestrogen levels. The first had recurrent pneumothoraces during her first pregnancy. The second lady was post menopausal at diagnosis but her symptoms predated her menopause. The third, presented with dyspnoea, abnormal chest sensations and a pneumothorax. She had a history of hyperprolactinaemia with secondary amenorhoea due to low oestrogen levels which had been corrected prior to her presentation. All three patients had reduced gas transfer and abnormalities in spirometry, two had reticular shadowing on their chest radiograph and all had typical appearances on lung computerised tomography. Although disease progression was variable, all patients showed a gradual decline in lung function.


Asunto(s)
Linfangioleiomiomatosis/diagnóstico , Linfangioleiomiomatosis/fisiopatología , Adulto , Femenino , Humanos , Linfangioleiomiomatosis/etiología , Linfangioleiomiomatosis/terapia , Persona de Mediana Edad , Neumotórax/etiología , Embarazo , Complicaciones del Embarazo/fisiopatología , Pruebas de Función Respiratoria
17.
J Natl Cancer Inst ; 92(23): 1926-34, 2000 Dec 06.
Artículo en Inglés | MEDLINE | ID: mdl-11106684

RESUMEN

BACKGROUND: Most breast cancers, even those that are initially responsive to tamoxifen, ultimately become resistant. The molecular basis for this resistance, which in some patients is thought to involve stimulation of tumor growth by tamoxifen, is unclear. Tamoxifen induces cellular oxidative stress, and because changes in cell redox state can activate signaling pathways leading to the activation of activating protein-1 (AP-1), we investigated whether tamoxifen-resistant growth in vivo is associated with oxidative stress and/or activation of AP-1 in a xenograft model system where resistance is caused by tamoxifen-stimulated growth. METHODS: Control estrogen-treated, tamoxifen-sensitive, and tamoxifen-resistant MCF-7 xenograft tumors were assessed for oxidative stress by measuring levels of antioxidant enzyme (e.g., superoxide dismutase [SOD], glutathione S-transferase [GST], and hexose monophosphate shunt [HMS]) activity, glutathione, and lipid peroxidation. AP-1 protein levels, phosphorylated c-jun levels, and phosphorylated Jun NH(2)-terminal kinase (JNK) levels were examined by western blot analyses, and AP-1 DNA-binding and transcriptional activities were assessed by electrophoretic mobility shift assays and a reporter gene system. All statistical tests are two-sided. RESULTS: Compared with control estrogen-treated tumors, tamoxifen resistant tumors had statistically significantly increased SOD (more than threefold; P=.004) and GST (twofold; P=.004) activity and statistically significantly reduced glutathione levels (greater than twofold; P<.001) and HMS activity (10-fold; P<.001). Lipid peroxides were not significantly different between control and tamoxifen-resistant tumors. We observed no differences in AP-1 protein components or DNA-binding activity. However, AP-1-dependent transcription (P=.04) and phosphorylated c-Jun and JNK levels (P<.001) were statistically significantly increased in the tamoxifen-resistant tumors. CONCLUSION: Our results suggest that the conversion of breast tumors to a tamoxifen-resistant phenotype is associated with oxidative stress and the subsequent antioxidant response and with increased phosphorylated JNK and c-Jun levels and AP-1 activity, which together could contribute to tumor growth.


Asunto(s)
Antineoplásicos Hormonales/farmacología , Neoplasias de la Mama/tratamiento farmacológico , Neoplasias de la Mama/metabolismo , Moduladores de los Receptores de Estrógeno/farmacología , Proteínas Quinasas Activadas por Mitógenos/metabolismo , Estrés Oxidativo , Tamoxifeno/farmacología , Factor de Transcripción AP-1/metabolismo , Animales , Antineoplásicos Hormonales/uso terapéutico , Western Blotting , Neoplasias de la Mama/enzimología , Neoplasias de la Mama/genética , Cloranfenicol O-Acetiltransferasa/análisis , ADN de Neoplasias/efectos de los fármacos , Modelos Animales de Enfermedad , Resistencia a Antineoplásicos , Moduladores de los Receptores de Estrógeno/uso terapéutico , Femenino , Glutatión Transferasa/metabolismo , Humanos , Proteínas Quinasas JNK Activadas por Mitógenos , Peroxidación de Lípido , Ratones , Ratones Desnudos , Vía de Pentosa Fosfato , Fenotipo , Fosforilación , Proteínas Proto-Oncogénicas c-jun/metabolismo , Superóxido Dismutasa/metabolismo , Tamoxifeno/uso terapéutico , Transcripción Genética/efectos de los fármacos , Trasplante Heterólogo
18.
Radiology ; 217(3): 713-22, 2000 Dec.
Artículo en Inglés | MEDLINE | ID: mdl-11110933

RESUMEN

PURPOSE: To investigate patient radiation exposures during uterine arterial embolization and the factors responsible for those exposures. MATERIALS AND METHODS: Clinical and procedural factors were evaluated for 42 consecutive procedures performed in 39 patients by one operator. Seven patients were excluded because of early termination (n = 1) or unusual conditions that necessitated extended procedures (n = 6). Fluoroscopic time, number of images acquired, height, and weight were available in the 35 remaining patients, and dose-area product (DAP) was available in 20. Equipment factors were evaluated by using a Lucite phantom in four angiography units from three manufacturers. RESULTS: The mean fluoroscopic time per case decreased from 30.6 to 14.2 minutes between the 1st and 5th quintiles. Mean DAP decreased from 211.4 to 30.6 Gy. cm(2) with dose reduction techniques; this primarily reflected a decreased number of acquired images. Phantom studies demonstrated many significant dose variations with magnification and equipment position. Low-dose and pulsed fluoroscopic modes reduced exposure rates in units so equipped, but roadmapping caused a silent switch to continuous fluoroscopy in two such units, which doubled the exposure rate. CONCLUSION: With operator experience and careful technique, uterine arterial embolization can be performed at radiation exposures comparable to those used in routine diagnostic studies. However, operators must be familiar with the technical parameters of their angiographic equipment.


Asunto(s)
Embolización Terapéutica/métodos , Fantasmas de Imagen , Dosis de Radiación , Útero/irrigación sanguínea , Adulto , Angiografía , Femenino , Fluoroscopía , Humanos
19.
Plant Physiol ; 124(3): 1349-62, 2000 Nov.
Artículo en Inglés | MEDLINE | ID: mdl-11080310

RESUMEN

Boron is an essential micronutrient for plant growth and the boron content of plants differs greatly, but the mechanism(s) of its uptake into cells is not known. Boron is present in the soil solution as boric acid and it is in this form that it enters the roots. We determined the boron permeability coefficient of purified plasma membrane vesicles obtained from squash (Cucurbita pepo) roots and found it to be 3 x 10(-7) +/-1.4 x 10(-8) cm s(-1), six times higher than the permeability of microsomal vesicles. Boric acid permeation of the plasma membrane vesicles was partially inhibited (30%-39%) by mercuric chloride and phloretin, a non-specific channel blocker. The inhibition by mercuric chloride was readily reversible by 2-mercaptoethanol. The energy of activation for boron transport into the plasma membrane vesicles was 10.2 kcal mol(-1). Together these data indicate that boron enters plant cells in part by passive diffusion through the lipid bilayer of the plasma membrane and in part through proteinaceous channels. Expression of the major intrinsic protein (MIP) PIP1 in Xenopus laevis oocytes resulted in a 30% increase in the boron permeability of the oocytes. Other MIPs tested (PIP3, MLM1, and GlpF) did not have this effect. We postulate that certain MIPs, like those that have recently been shown to transport small neutral solutes, may also be the channels through which boron enters plant cells.


Asunto(s)
Acuaporinas/metabolismo , Ácidos Bóricos/metabolismo , Cucurbitaceae/metabolismo , Proteínas de Escherichia coli , Canales Iónicos/metabolismo , Proteínas de Plantas/metabolismo , Vesículas Transportadoras/metabolismo , Animales , Proteínas de la Membrana Bacteriana Externa/metabolismo , Transporte Biológico , Permeabilidad de la Membrana Celular , Cucurbitaceae/fisiología , Mercaptoetanol/farmacología , Cloruro de Mercurio/farmacología , Oocitos , Floretina/farmacología , Raíces de Plantas/metabolismo , Raíces de Plantas/fisiología , Xenopus laevis
20.
Clin Cancer Res ; 6(9): 3696-704, 2000 Sep.
Artículo en Inglés | MEDLINE | ID: mdl-10999763

RESUMEN

Retinoids have been investigated as potential agents for the prevention and treatment of human cancers. These compounds play an important role in regulating cell growth, differentiation, and apoptosis. 9-cis-Retinoic acid (9cRA) is a naturally occurring ligand with a high affinity for both the retinoic acid receptors and the retinoid X receptors. We hypothesized that treatment with 9cRA would prevent mammary tumorigenesis in transgenic mice that spontaneously develop mammary tumors. To test this hypothesis, C3(1)-SV40 T antigen (Tag) mice, which develop mammary tumors by the age of 6 months, were treated daily p.o. with vehicle or two different dose levels of 9cRA (10 or 50 mg/kg) from 5 weeks to 6 months of age. Tumor size and number were measured twice each week, and histological samples of normal and malignant tissue were obtained from each mouse at time of sacrifice. Our results demonstrate that 9cRA suppresses mammary tumorigenesis in C3(1)-SV40 Tag-transgenic mice. Time to tumor development was significantly delayed in treated mice; median time to tumor formation for vehicle-treated mice was 140 days versus 167 days for mice treated with 50 mg/kg 9cRA (P = 0.05). In addition, the number of tumors per mouse was reduced by >50% in mice treated with 9cRA (3.43 for vehicle, 2.33 for 10 mg/kg 9cRA, and 1.13 for 50 mg/kg 9cRA, P < or = 0.002). Histological analysis of the mammary glands from vehicle and treated mice demonstrated that 9cRA treatment also did not affect normal mammary gland development. Immunohistochemical staining of normal and malignant breast tissue and Western blot analysis demonstrated that SV40 Tag expression was not affected by treatment with retinoids. Single doses of 10 and 50 mg/kg resulted in peak plasma concentrations of 3.4 and 6.71 microM, respectively. Daily doses of 9cRA for 28 days resulted in plasma concentrations of 0.86 and 1.68 microM, respectively, concentrations consistent with that seen in humans treated with 9cRA in clinical trials. These results demonstrate that 9cRA suppresses mammary carcinogenesis in transgenic mice without any major toxicity and suggest that retinoids are promising agents for the prevention of human breast cancer.


Asunto(s)
Anticarcinógenos/farmacología , Transformación Celular Neoplásica/efectos de los fármacos , Neoplasias Mamarias Experimentales/prevención & control , Tretinoina/farmacología , Alitretinoína , Animales , Antígenos Transformadores de Poliomavirus/biosíntesis , Antígenos Transformadores de Poliomavirus/genética , Transformación Celular Neoplásica/genética , Femenino , Expresión Génica/efectos de los fármacos , Neoplasias Mamarias Experimentales/genética , Neoplasias Mamarias Experimentales/inmunología , Ratones , Ratones Transgénicos , Tretinoina/sangre
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA
...